

Curriculum vitae
Roberto Pisoni, MD

Personal Data

Name: Roberto Pisoni
Citizenship: Italian
VISA Status: US Permanent Resident
Date and Place of Birth: October 19, 1969 - Bergamo, Italy
Work Address: Suite 829 CSB
Medical University of South Carolina
96 Jonathan Lucas SC, Charleston, SC 29425
Preferred Phone: 843-792-4123
Preferred Fax: 843-792-8399
E-mail: pisoni@musc.edu
Languages: Italian and English

Education and Training

1983 - 1988 High School at Collegio S.Alessandro in Bergamo, Italy
1988 - 1995 Medical School, University of Pavia, Italy
May - October 1995 Internship in Internal Medicine, University of Pavia, Italy
1996 - 2003 Clinical Investigator, Department of Renal Medicine, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
January - June 1997 Fellowship in Hematology, University of Parma, Italy
1999 - 2003 Fellowship in Nephrology, University of Florence, Italy in conjunction with Mario Negri Institute for Pharmacological Research, Bergamo, Italy and Ospedali Riuniti di Bergamo, Bergamo, Italy
June 2004 - June 2007 Internal Medicine Residency, Carraway Methodist Medical Center, Birmingham, AL
July 2007 - June 2010 Nephrology Fellowship, University of Alabama at Birmingham, Birmingham, AL
July 2008 - August 2010 Postdoctoral Research Fellowship, NIH T32HL0074527-29 Training Program in 'Mechanisms of Hypertension and Cardiovascular Diseases', Principal Investigator: Suzanne Oparil, MD, Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL
July 2009 - June 2010 Without Compensation (WOC) Physician Appointment at the Birmingham Veteran Affairs Medical Center, Birmingham, AL
October 2010 - present Assistant Professor, College of Medicine, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC
January 2011- present Medical Director of Dialysis Clinic Inc. Facility located at 2270 Technical Pkwy, North Charleston, SC

Honors

March 1995 Medical Degree, cum laude, University of Pavia, Italy
March 2003 Fellowship Degree in Nephrology, cum laude, University of Florence, Italy in conjunction with Mario Negri Institute for Pharmacological Research, Bergamo, Italy and Ospedali Riuniti, Bergamo, Italy

April 13, 2010

Selected and participated in the 5th Annual National Young Investigators Forum, National Kidney Foundation 2010 Spring Clinical Meetings, Orlando, FL

Certifications

November 1995

Italian Medical Licensure, University of Pavia, Italy

December 15, 2003

ECFMG Certified

August 14, 2007

Internal Medicine Board Certified

November 18, 2009

Nephrology Board Certified

Teaching Activity

2009 - 2010

Preceptor of five medical students for the 'Introduction to Clinical Medicine II (ICM II): Clinical Skills and Physical Diagnosis', University of Alabama at Birmingham, Birmingham, AL

Areas of Clinical Research Interest

Mechanisms of progression of chronic kidney disease

Primary and secondary prevention of type 2 diabetic nephropathy

Resistant hypertension in chronic kidney disease

Publications

Original Research

1. **Pisoni R**, Barker-Finkel J, Allon M. Statin therapy is not associated with improved vascular access outcomes. *Clin J Am Soc Nephrol* 5:1447-50, 2010
2. Ruggenenti P, Mise N, **Pisoni R**, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. *Circulation* 107(4):586-92, 2003
3. **Pisoni R**, Ruggenenti P, Sangalli F, Lepre MS, Remuzzi A, Remuzzi G. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. *Kidney Int* 62(3):1010-9, 2002
4. Ruggenenti P, Perna A, Lesti M, **Pisoni R**, Mosconi L, Arnoldi F, Ciocca I, Gaspari F, Remuzzi G. Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group. *Kidney Int* 58(5):2093-101, 2000
5. Gaspari F, Perico N, **Pisoni R**, Anedda MF, Signorini O, Caruso R, Gotti E, Remuzzi G. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? *Clin Transplant* 12(5):379-90, 1998
6. Ruggenenti P, Perna A, Mosconi L, **Pisoni R**, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). *Kidney Int* 53(5):1209-16, 1998
7. Ruggenenti P, Perna A, Mosconi L, Matalone M, **Pisoni R**, Gaspari F, Remuzzi G. The nephroprotective effect of ACE inhibitors. *Results of the ramipril efficacy in nephropathy (REIN) study*. In: ACE inhibition and target organ protection. Hoechst Marion Roussel, Bridgewater, USA;87-94, 1998
8. Ruggenenti P, Perna A, Mosconi L, Matalone M, **Pisoni R**, Gaspari F, Remuzzi G. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia"(GISEN). *Kidney Int* 63:S54-7, 1997
9. Ruggenenti P, Perna A, Mosconi L, Matalone M, **Pisoni R**, Gaspari F, Remuzzi G, GISEN Group. The REIN study. In: *ACE inhibition and renoprotection*. Hoechst Marion Roussel, Bridgewater, US; 73-81, 1997

Reviews

1. **Pisoni R**, Ahmed MI, Calhoun D. Characterization and treatment of resistant hypertension. *Curr Cardiol Rep* 11(6):407-13, 2009
2. Ahmed MI, **Pisoni R**, Calhoun D. Current options for the treatment of resistant hypertension. *Expert Rev Cardiovasc Ther* 7(11):1385-93, 2009
3. **Pisoni R**, Wille K, Tolwani A. The epidemiology of severe acute kidney injury: from BEST to PICARD, in acute kidney injury: new concepts. *Nephron Clin Pract* 109:c188-91, 2008
4. Ruggenenti P, **Pisoni R**, Remuzzi A, Remuzzi G. The antiproteinuric effect of high-dose ramipril: Still an open question. *Kidney Int* 63(2):770-1, 2003
5. **Pisoni R**, Ruggenenti P, Remuzzi G. Thrombotic microangiopathies including hemolytic uremic syndrome. In Johnson RJ, Feehally J, Eds. *Comprehensive Clinical Nephrology*, edn 2. Mosby 413-23, 2003
6. **Pisoni R**, Remuzzi G. Hemolytic uremic syndrome. In Robert R, Lameire N, Eds. *Insuffisance renale aigue en reanimation*. Elsevier Paris: 232-42, 2003
7. **Pisoni R**, Ruggenenti P, Remuzzi G. Terapia della microangiopatia trombotica. In Pasquali S, Roccatello D, Pani A, Manno C, Onetti Muda A, Cagnoli L, Eds. *Manuale di Terapia delle Nefropatie Glomerulari*. Wichtig Editore Milano: 185-94, 2003
8. **Pisoni R**, Faraone R, Ruggenenti P, Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. *J Nephrol* 15(4):428-30, 2002
9. **Pisoni R**, Aros C, Ruggenenti P, Remuzzi G. Mechanisms of progression of chronic renal disease. *Saudi J Kidney Dis Transplant* 13:250-6, 2002
10. **Pisoni R**, Ruggenenti P, Remuzzi G. Renoprotective therapy in patients with nondiabetic nephropathies. *Drugs* 61(6):733-45, 2001
11. **Pisoni R**, Remuzzi G. Pathophysiology and management of progressive chronic renal failure. In National Kidney Foundation: *Primer on Kidney Diseases*, edn 3. Edited by Greenberg A. San Diego: Academic Press 385-96, 2001
12. **Pisoni R**, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. *Drug Saf* 24(7):491-501, 2001
13. **Pisoni R**, Schieppati A, Ruggenenti P, Remuzzi G. Il controllo del decorso della nefropatia diabetica e le implicazioni dello studio RENAAL. *Ann Ital Med Int* 16(3):13-16S, 2001
14. **Pisoni R**, Remuzzi G. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? *J Nephrol* 13(3):228-31, 2000
15. **Pisoni R**, Remuzzi G. Thrombotic microangiopathy. *Eur J Intern Med* 11:135-39, 2000
16. Ruggenenti P, **Pisoni R**, Remuzzi G. Emolitica-uremica sindrome. In *Enciclopedia Medica Italiana*, aggiornamento 2. Edited by USES Firenze 1849-62, 1998

Poster Presentations

1. **Pisoni R**, Acelayado CM, Oparil S, Calhoun D. Effects of aldosterone receptor blockers in resistant hypertension and stage 3 chronic kidney disease. *National Kidney Foundation Spring Clinical Meetings*, 2010

2. **Pisoni R**, Allon M. Statin use is not associated with improved access outcomes in patients with chronic kidney disease stage IV-V receiving an upper arm vascular access. *J Am Soc Nephrol* PO2500, 2009
3. Mise N, **Pisoni R**, Ruggenenti P, Perna A, Gaspari F, Brenner BM, Remuzzi G. Dose-dependent amelioration of dyslipidemia by maximum tolerated doses of lisinopril in nephrotic patients with non diabetic chronic nephropathies. *J Am Soc Nephrol* A0608, 2001
4. Parvanova A, **Pisoni R**, Dimitrov B, Iliev I, Perna A, Ruggenenti P, Stucchi N, Lutz J, Remuzzi G. Relative renoprotective effect of ACE inhibitors (ACEi), angiotensin II antagonists (ATA), ACEi and ATA combination, and dihydropyridine calcium channel blockers (dCCBs) in overt nephropathy of type 2 diabetes. *J Am Soc Nephrol* A0802, 2001
5. Perna A, Lesti M, **Pisoni R**, Arnoldi F, Ciocca I, Mosconi L, Gaspari F, Remuzzi G, Ruggenenti P. How best measuring blood pressure (BP) in the context of chronic progressive nephropathies. *J Am Soc Nephrol* A0404, 2000
6. **Pisoni R**, Grinyo JM, Salvadori M, Laurens W, Garini G, Oliver YA, Mezzano S, Ruggenenti P, Remuzzi G. Cyclosporine versus conservative therapy in patients with idiopathic membranous nephropathy (IMN) and deteriorating renal function: Results of the CYCLOMEN trial. *J Am Soc Nephrol* A0514, 2000
7. Ruggenenti P, Perna A, Zoccali C, Ferrari S, Del Priore L, Cattaneo D, **Pisoni R**, Mosconi L, Testa A, Remuzzi G. Among patients with proteinuric chronic nephropathies, gender and ACE genotype identify responders to ACE inhibition. *J Am Soc Nephrol* A0442, 1999
8. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Mosconi L, **Pisoni R**, del Priore L, Tammuzzo L, Remuzzi G. Rein follow-up trial: no more GFR decline or need of dialysis after long-enough ACE inhibition in chronic nephropathies. *J Am Soc Nephrol* A0820, 1998
9. Gaspari F, Perico N, **Pisoni R**, Anedda MF, Signorini O, Gotti E, Remuzzi G. Conversion from sandimmune to neoral at two different dose-ratio in stable renal transplant patients. *J Am Soc Nephrol* A3314, 1997